News Headline Summary

FDA expands Johnson & Johnson (JNJ) Zyriga's use for late-stage prostate cancer

Reaction details:

- Johnson & Johnson's shares are unmoved by this latest commentary from Johnson & Johnson; trades USD 70.72 last (+0.4%).

Print 18:22, 10 Dec 2012 - US Equities - Source: Newswires